Head & Neck Cancers | Specialty

The Future of RAI-Refractory DTC Management

February 11th 2021

Frontline Durvalumab Fails to Improve OS in Recurrent or Metastatic HNSCC

February 5th 2021

February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.

Rationale for Sequencing in Second Line

February 4th 2021

LIBRETTO-001 Phase 1/2 Trial Overview

February 4th 2021

Advice for Managing RAI-Refractory DTC

January 28th 2021

Molecular Testing in Treatment Selection

January 28th 2021

Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer

January 21st 2021

Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.

Sorafenib and Lenvatinib Side Effect Profile and Dosing

January 21st 2021

RAI-Refractory DTC Trials: Phase 3 DECISION and SELECT

January 21st 2021

28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

January 18th 2021

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Multidisciplinary Management for the Treatment of DTC

January 18th 2021

Approaching Treatment of Low-Volume DTC

January 18th 2021

Understanding Sequencing and What to Look for in DTC

January 18th 2021

Roles and Communication in Treatment in DTC

January 11th 2021

Management of DTC in Clinical Practice

January 11th 2021

NICE Rejects Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

January 8th 2021

January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy.

Discussing Iodine-Refractory DTC With Patients

January 4th 2021

Clinical Scenarios to Consider for RAI-Refractory DTC

January 4th 2021

Lindau on Leading Successful Surgical Fellowships

December 31st 2020

In our exclusive interview, Robert Lindau, III, MD, discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.

SGX942 Shows Meaningful Reduction in Oral Mucositis in Head and Neck Cancer, But Not Statistically Significant

December 23rd 2020

December 23, 2020 — Although SGX942 was found to induce clinically meaningful reductions in severe oral mucositis vs placebo in patients with head and neck cancer, the benefit failed to reach statistical significance, thus missing the primary end point of the phase 3 DOM-INNATE study.